

300436

2025009



/ 3CL  
® Tazovid®  
PLATCOV TFDA

Finding treatments for COVID-19: A phase 2 multi-centre  
adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic

COVID-19 (PLATCOV) COVID-19 COVID-19  
2 PLATCOV

VIR21001

1 / ®  
Tazovid® 2 PAXLOVID  
ACT-Accelerator

PLATCOV 2

COVID-19

COVID-19

11  
COVID19  
Paxlovid P  
1/2 II/III  
2 5  
-1.75 log<sub>10</sub> copies/mL 2024 4 II/III  
-eClinicalMedicine 2024 11  
2025 1

PLATCOV

TFDA

2025 2 5